Blank Rome hires new patent agent for Texas office
Blank Rome has brought in patent agent Joseph Jackson to the firm’s IP and Technology practice group in Houston.
BMS sues AstraZeneca for infringing cancer treatment drug
US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.
FTC targets ‘Pharma Bro’ Martin Shkreli over start-up
Commission holds that the convicted former pharma head may have violated his life-long ban from working in the life sciences industry | Shkreli is already convicted of conspiring to illegally increase the price of a life-saving drug.
Report: Market for anti-counterfeit drugs packaging to hit $191bn by 2030
New study examines industry by product, application and region | China, Germany and India predicted to see the largest growth.
Jazz Pharma’s medical cannabis unit seeks to block generic
UK-based cannabidiol lab sues firms behind proposed ANDA | Feud centres on a cannabis treatment for epilepsy.
Cohausz & Florack hires senior technical duo
Cohausz & Florack has added two new partners to the team to further expand the firm’s IP expertise in key technical areas.
Withers hires senior duo from Brown Rudnick to Boston office
Leader of Brown Rudnik’s IP practice moves to US office of London firm | Boston office continues growth.
L’Oreal prevails in anti-aging treatment clash
Dispute concerns two of the cosmetic giant’s best-selling brands | Arguments revolved around whether the French company could be sued in the US.
Drugs to Watch report: 15 blockbusters for 2023
Clarivate study highlights treatments with blockbuster potential | IV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer make the list | Nine blockbusters from China also predicted.
Gilead avoids $1.2bn patent clash at SCOTUS
Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
